{"id":109887,"date":"2025-04-17T06:27:00","date_gmt":"2025-04-17T09:27:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-announces-succession-chairmen-shareholders-committee-and-board-of-managing-directors\/"},"modified":"2025-04-17T06:27:00","modified_gmt":"2025-04-17T09:27:00","slug":"boehringer-ingelheim-announces-succession-chairmen-shareholders-committee-and-board-of-managing-directors","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-announces-succession-chairmen-shareholders-committee-and-board-of-managing-directors\/","title":{"rendered":"Boehringer Ingelheim announces succession Chairmen Shareholders Committee and Board of Managing Directors"},"content":{"rendered":"<div>\n<div>\n<ul role=\"list\">\n<li data-leveltext=\"\" data-font=\"Boehringer Text\" data-listid=\"1\" data-aria-posinset=\"1\" data-aria-level=\"3\" role=\"listitem\">\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span data-ccp-parastyle=\"List Bullet 2\">Christian Boehringer to hand o<\/span><span data-ccp-parastyle=\"List Bullet 2\">ver as <\/span><span data-ccp-parastyle=\"List Bullet 2\">Chairman<\/span><span data-ccp-parastyle=\"List Bullet 2\"> of the Shareholders Committee to Hubertus von <\/span><span data-ccp-parastyle=\"List Bullet 2\">Baumbach<\/span><\/span><span>\u00a0<\/span><\/strong><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul role=\"list\">\n<li data-leveltext=\"\" data-font=\"Boehringer Text\" data-listid=\"1\" data-aria-posinset=\"2\" data-aria-level=\"3\" role=\"listitem\" style=\"font-weight: bold\" data-mce-style=\"font-weight: bold;\">\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span data-ccp-parastyle=\"List Bullet 2\">Shashank Deshpande, Member of th<\/span><span data-ccp-parastyle=\"List Bullet 2\">e Board of Managing Directors, to succeed Hubertus von Baumbach as <\/span><span data-ccp-parastyle=\"List Bullet 2\">Chairman<\/span><span data-ccp-parastyle=\"List Bullet 2\"> of the Board of Managing Directors<\/span><\/span><span>\u00a0<\/span><\/strong><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul role=\"list\">\n<li data-leveltext=\"\" data-font=\"Boehringer Text\" data-listid=\"1\" data-aria-posinset=\"3\" data-aria-level=\"3\" role=\"listitem\" style=\"font-weight: bold\" data-mce-style=\"font-weight: bold;\">\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span data-ccp-parastyle=\"List Bullet 2\">Appointments to be effective July 1, 2025<\/span><\/span><span>\u00a0<\/span><\/strong><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span \/><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>The Shareholders Committee of Boehringer Ingelheim have announced the following appointments in the Shareholders Committee and the Board of Managing Directors:<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Christian Boehringer<\/span><\/span><\/strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>, since 2007 <\/span><span>Chairman<\/span><span> of the Shareholders Committee, has decided to step down from his role<\/span><span> with effect from June 30, <\/span><span>2025<\/span><span>. The Shareholders Committee has <\/span><span>appointed<\/span><span>\u00a0<\/span><\/span><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Hubertus von Baumbach<\/span><\/span><\/strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>, currently <\/span><span>Chairman<\/span><span> of the Board of Directors, as his successor, effective July 1, 2025.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Shashank Deshpande<\/span><\/span><\/strong><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>, member of the Board of Managing Directors, has been appointed <\/span><span>Chairman<\/span><span> of the Board of Managing Directors, a responsibility that he will take on in addition to his current role leading the Human Pharma Business Unit. He will take over the Chairmans mandate from Hubertus von Baumbach <\/span><span>per<\/span><span> July 1, 2025.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Christian Boehringer commented: I look back at the past 18 years with great fulfillment, having worked with three CEOs and seen Boehringer grow to become the global pharma company it is today. I now hand over the baton to my cousin Hubertus, and very much look forward to working together with him on the Shareholders Committee.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span role=\"presentation\"><span \/><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Hubertus von Baumbach served 16 years on the Board of Managing Directors, nine of which as <\/span><span>Chairman<\/span><span>. He added: I want to thank Christian for his many years of leadership and dedication to the company. During his <\/span><span>tenure<\/span><span> the company changed fundamentally. I am very thankful for the trust I have been given <\/span><span>with<\/span><span> my new role. I wish Shashank much success; with his many years of industry experience in the US, <\/span><span>Japan<\/span><span> and Germany, he will lead Boehringer through the next growth phase towards 2035. In <\/span><span>the many years that I have worked with Shashank I have seen and come to appreciate the strength of his leadership, of his values, and of his commitment to patients.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Shashank Deshpande responded: I am thankful that the shareholders entrust me with the Chairmans role on the Board. I want to acknowledge Hubertus leadership of the company these past nine years. <\/span><span>Youve<\/span><span> built <\/span><span>a great team<\/span><span> and <\/span><span>its<\/span><span> a true pleasure to be part of it. We are fully focused on bringing our strong pipeline to the market as fast as possible, and I am highly motivated to lead our organization to achieve this for the benefit of the patients and animals we serve.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"DE-DE\" lang=\"DE-DE\"><span>Hubertus von Baumbach <\/span><span>joined<\/span><span> Boehringer Ingelheim <\/span><span>in 2001<\/span><span>. <\/span><\/span><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>He held various leadership positions in Finance &amp; Controlling, until he was appointed to the Board of Managing Directors in 2009, initially with responsibility for Finance and Animal Health, and from 2016 as <\/span><span>Chairman<\/span><span> of the Board.<\/span><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span>Shashank Deshpande joined Boehringer Ingelheim in 2012, following a decade in pharma in the US. He took on various human pharma leadership positions in Germany and Japan, <\/span><span>ultimately as<\/span><span> Country Managing Director Japan. In 2023, Deshpande joined the Board of Managing Directors, with responsibility for Animal Health. In 2024, he was given responsibility for Human Pharma. Shashank Deshpande holds a <\/span><span>Masters degree in Business Administration<\/span><span> from the University of Hamburg, Germany.<\/span><\/span><span>\u00a0<\/span><\/p>\n<div>\n<a href=\"https:\/\/www.boehringer-ingelheim.com\/disclaimer\/external?path=https%3A%2F%2Fbrand.boehringer-ingelheim.com%2Fdocument%2F649%23%2F-%2Foverview\" title=\"Link to our image pool\" data-once=\"biDisclaimerLinkCheck ajax\" data-dialog-type=\"modal\" data-it-button=\"Link to our image pool\" data-mce-href=\"https:\/\/www.boehringer-ingelheim.com\/disclaimer\/external?path=https%3A%2F%2Fbrand.boehringer-ingelheim.com%2Fdocument%2F649%23%2F-%2Foverview\"><span>\u00a0<\/span><strong>Link to our image pool<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.boehringer-ingelheim.com\/about-us\/who-we-are\/leadership\" data-once=\"biDisclaimerLinkCheck\" data-it-button=\"Link to our Leadership\" data-mce-href=\"https:\/\/www.boehringer-ingelheim.com\/about-us\/who-we-are\/leadership\"><strong>Link to our Leadership<\/strong><\/a><\/p>\n<\/div>\n<div>\n<span>\u00a0<\/span><\/p>\n<div>\n<span lang=\"EN-US\"><strong>Boehringer Ingelheim<\/strong><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<div>\n<span lang=\"EN-US\">Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industrys top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.<span>\u00a0<\/span><\/span><span lang=\"DE-DE\">Learn<\/span><span lang=\"DE-DE\"><span>\u00a0<\/span><\/span><span lang=\"DE-DE\">more<\/span><span lang=\"DE-DE\"><span>\u00a0<\/span>atwww.boehringer-ingelheim.com.\u00a0<\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div>\n<p><span data-contrast=\"auto\" xml:lang=\"EN-US\" lang=\"EN-US\"><span \/><\/span><span>\u00a0<\/span><\/p>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA4MDkxNiM0MDIxMTU1MzcjMjIwNTExMQ==\" \/> <br \/><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZTM0YjdkODEtOTNmNy00MGU2LThmMzAtMDFjODk2ZjY0M2M0LTEyMTY2NjQtMjAyNS0wNC0xNy1lbg==\/tiny\/Boehringer-Ingelheim-Limited.png\" \/><br \/>\n<a href=\"https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/f121dfae-77e7-4a01-b1ef-6b757767ddab\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/f121dfae-77e7-4a01-b1ef-6b757767ddab\/small\/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png\" border=\"0\" width=\"150\" height=\"46\" alt=\"Primary Logo\" \/><\/a><\/p>\n<p>A <b>OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da <b>OESP<\/b> e sao de inteira responsabilidade da <b>GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"Christian Boehringer to hand over as Chairman of the Shareholders Committee to Hubertus von Baumb","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-109887","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/109887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=109887"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/109887\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=109887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=109887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=109887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}